Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Oct;94(42):e1604.
doi: 10.1097/MD.0000000000001604.

Relationship Between Myo-Inositol Supplementary and Gestational Diabetes Mellitus: A Meta-Analysis

Xiangqin Zheng  1 , Zhaozhen Liu, Yulong Zhang, Yuan Lin, Jianrong Song, Lianghui Zheng, Sheng Lin
Affiliations
Meta-Analysis

Relationship Between Myo-Inositol Supplementary and Gestational Diabetes Mellitus: A Meta-Analysis

Xiangqin Zheng et al. Medicine (Baltimore). 2015 Oct.

Abstract

To determine whether myo-inositol supplement will increase the action of endogenous insulin, which is mainly measured by markers of insulin resistance such as homeostasis model assessment of insulin resistance.PubMed, Cochrane Library, Embase, and web of science were comprehensively searched using "gestational diabetes mellitus" and "myo-inositol" to identify relevant studies. Both subject headings and free texts were adopted. The methodological quality of the included studies were assessed and pooled analyzed by the methods recommended by the Cochrane collaboration.A total of 5 trials containing 513 participants were included. There was a significant reduction in aspects of gestational diabetes incidence (risk ratio [RR], 0.29; 95% confidence interval (95% CI), 0.19-0.44), birth weight (mean difference [MD], -116.98; 95% CI, -208.87 to -25.09), fasting glucose oral glucose tolerance test (OGTT) (MD, -0.36; 95% CI, -0.51 to -0.21), 1-h glucose OGTT (MD, -0.63; 95% CI, -1.01 to -0.26), 2-h glucose OGTT (MD, -0.45; 95% CI, -0.75 to -0.16), and related complications (odds ratio [OR], 0.28; 95% CI 0.14-0.58).On the basis of current evidence, myo-inositol supplementation reduces the development of gestational diabetes mellitus (GDM), although this conclusion requires further evaluation in large-scale, multicenter, blinded randomized controlled trials.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicting interests.

Figures

FIGURE 1
FIGURE 1
Flow chart of trial selection from initial literature search to final studies inclusion.
FIGURE 2
FIGURE 2
Meta-analysis result of the incidence of gestational diabetes between the groups.
FIGURE 3
FIGURE 3
Meta-analysis result of birth weight between the groups.
FIGURE 4
FIGURE 4
Meta-analysis result of fasting glucose OGTT between the groups.
FIGURE 5
FIGURE 5
Meta-analysis result of 1-h glucose OGTT between the groups.
FIGURE 6
FIGURE 6
Meta-analysis result of 2-h glucose OGTT between the groups.
FIGURE 7
FIGURE 7
Meta-analysis result of the incidence of gestational diabetes mellitus related complications.
See this image and copyright information in PMC

References

    1. American College of Obstetricians and Gynecologists Practice Bulletin. Clinical management guidelines for obstetrician gynecologists. Number 30, September 2001 (replaces Technical Bulletin Number 200, December 1994). Gestational diabetes. Obstet Gynecol 2001; 98:525–538. - PubMed
    1. Teh WT, Teede HJ, Paul E, et al. Risk factors for gestational diabetes mellitus: implications for the application of screening guidelines. Aus N Z J Obstet Gynaecol 2011; 51:26–30. - PubMed
    1. Ferrara A. Increasing prevalence of gestational diabetes mellitus: a public health perspective. Diabetes Care 2007; 30 Suppl 2:S141–S146. - PubMed
    1. Ryan EA. Diagnosing gestational diabetes. Diabetologia 2011; 54:480–486. - PMC - PubMed
    1. Oostdam N, van Poppel MN, Wouters MG, et al. Interventions for preventing gestational diabetes mellitus: a systematic review and meta-analysis. J Womens Health (Larchmt) 2011; 20:1551–1563. - PubMed

Publication types